First patients receive new 'T-Cell Engager' drug in early cancer trial

NCT ID NCT06402201

Summary

This is the first time a new drug called CDR404 is being tested in people. It is designed for adults with advanced solid tumors that have a specific protein called MAGE-A4 and a specific genetic marker (HLA-A*02:01). The main goals are to find a safe dose and see if the drug shows any early signs of fighting the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SELECT ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cliniques Universitaires Saint-Luc, UCL Ouvain

    RECRUITING

    Brussels, 1200, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, 46026, Spain

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)

    RECRUITING

    Barcelona, 08908, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Jules Bordet

    RECRUITING

    Brussels, 1070, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Instituto de Investigacion Sanitaria (INCLIVA)

    RECRUITING

    Valencia, 46026, Spain

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Isituto Europeo di Oncologia (IEO)

    RECRUITING

    Milan, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Istituto Clinico Humanitas

    RECRUITING

    Milan, 20089, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Pennsylvania Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Providence Cancer Institute

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Phone: •••-•••-••••

    Contact Email: •••••@•••••

    Contact

  • Rigshospitalet

    RECRUITING

    Copenhagen, DK-2100, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Marsden Hospital

    RECRUITING

    Sutton, London, SM2 5PT, United Kingdom

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Madrid

    RECRUITING

    Madrid, 28050, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • Universitair Ziekenhuis Antwerpen

    RECRUITING

    Antwerp, 2650, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, 9000, Belgium

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact

    Contact Email: •••••@•••••

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.